Related Experiment Videos
Prostaglandin E1-induced hyperostosis: clinicopathologic correlations and possible pathogenetic mechanisms
O M Faye-Petersen1, W H Johnson, W A Carlo
1Department of Pathology, University of Alabama at Birmingham, USA. ONAMARIE@lh.path.uab.edu
Summary
Prostaglandin E1 (PGE1) causes bone growth (hyperostosis) in infants, forming new bone layers. This reversible effect, potentially useful for fracture healing, is not always visible on X-rays initially.
Area of Science:
- Bone biology
- Pediatric pharmacology
- Medical imaging
Background:
- Prostaglandin E1 (PGE1) is used to maintain ductus arteriosus patency in neonates with congenital heart disease.
- PGE1 administration can lead to skeletal hypertrophy (bone growth), described radiologically as 'bone within bone'.
- Skeletal histopathology of this effect has not been previously studied.
Observation:
- Infants receiving continuous PGE1 (0.1-0.2 microgram/kg/min) were compared to controls.
- Bone samples were analyzed grossly, radiologically, and histologically after 4, 27, and 56 days of PGE1 treatment.
- Early periosteal osteoblast proliferation was observed after 27 days, with significant neocortex formation by 56 days.
Findings:
- PGE1 induced a dose-dependent and reversible hyperostosis.
- Histopathology revealed thickened periosteum, fibrocartilage-like tissue, and woven bone formation.
- A vascular reaction with orthogonally oriented capillaries appeared important for the bone hypertrophy.
- Cortical bone resorption was a secondary effect due to stress shielding by the neocortex.
Implications:
- PGE1-associated bone hypertrophy is distinct from inflammatory bone conditions.
- Early stages of PGE1-induced bone changes may not be detectable via radiography.
- The time course suggests potential therapeutic applications of PGE1 for conditions like ununited fractures with 4-8 weeks of use.